



## IBA to present Compact Proton Therapy at ASTRO Annual meeting 2013

**IBA makes proton therapy accessible for all cancer care departments with Proteus<sup>®</sup>ONE, its compact Proton Therapy solution, and its complete range of solutions and services.**

**Louvain-la-Neuve, Belgium September 20th, 2013 - IBA (Ion Beam Applications SA),** the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it will present its complete range of proton therapy solutions and services at ASTRO annual meeting in Atlanta, GA (Booth #1543). These solutions make proton therapy within reach of radiation therapy departments to complete their cancer care continuum.

This year's edition of ASTRO annual meeting will feature:

- A full size demonstration of the final design of Proteus<sup>®</sup>ONE treatment room. Proteus<sup>®</sup>ONE\* is a compact and affordable proton therapy treatment solution that brings proton therapy within reach for more facilities in a comfortable and reassuring environment improving both patient and staff satisfaction. Proteus<sup>®</sup>ONE is the safest way to compact IMPT.  
*\*Some features are under development and will be subject to review by qualified regulatory authorities.*
- A demonstration of IBA's treatment suite will show you how easy it is to deliver a proton therapy treatment.
- IBA services and training solutions. With 25 years of experience in developing, installing and operating proton therapy centers, IBA is the only player that is able to offer a full range of services and training that enhance everyday's proton therapy clinical practice.

Finally, IBA will be honored to support the organization of a Proton Therapy symposium\*\* hosted by the University of Florida College of Medicine: *"Hope, Guidance, and Healing: Necessary Components of Effective Proton Therapy and Clinical Research"*. This symposium will be followed by a reception hosted by IBA.

*\*\*Pre-registration is required to attend and capacity is limited. This activity is supported by an educational grant from IBA. The University of Florida College of Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.*



## Notes to Editors

### About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced side effects. Protons deposit the majority of their effective energy within a precisely controlled range within a tumour, sparing healthy surrounding tissue. Higher doses can be delivered to the tumour without increasing the risk of side effects and long-term complications, improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide use IBA solutions. This includes 15 proton therapy centres in operation and 11 centres under development. Over 25,000 patients have been treated with IBA equipment – representing more than all competitor installations combined.

### About Proteus<sup>®</sup> ONE\*

IBA Proteus<sup>®</sup> ONE is a compact single-room proton therapy solution. It benefits from the latest technologies of Proteus<sup>®</sup> PLUS, developed with top clinical institutions worldwide. Proteus<sup>®</sup> ONE is the safest way to compact Intensity Modulated Proton Therapy (IMPT), the most advanced radiotherapy modality. Proteus<sup>®</sup> ONE is smaller, more affordable, easier to install, easier to operate and ultimately to finance. With Proteus<sup>®</sup> ONE, protons are possible for more patients worldwide.

*\*Proteus<sup>®</sup> ONE is the brand name of a new configuration of the Proteus<sup>®</sup> 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.*

### About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of



medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

**For further information please contact:**

**IBA**

Olivier de Sadeleer  
Marketing Manager PT  
+32 10 475 890  
[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)